AU6887996A - Method of reducing neurotoxic injury with zinc chelators - Google Patents
Method of reducing neurotoxic injury with zinc chelatorsInfo
- Publication number
- AU6887996A AU6887996A AU68879/96A AU6887996A AU6887996A AU 6887996 A AU6887996 A AU 6887996A AU 68879/96 A AU68879/96 A AU 68879/96A AU 6887996 A AU6887996 A AU 6887996A AU 6887996 A AU6887996 A AU 6887996A
- Authority
- AU
- Australia
- Prior art keywords
- neurotoxic injury
- zinc chelators
- reducing neurotoxic
- reducing
- chelators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000027418 Wounds and injury Diseases 0.000 title 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title 1
- 239000002738 chelating agent Substances 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 231100000189 neurotoxic Toxicity 0.000 title 1
- 230000002887 neurotoxic effect Effects 0.000 title 1
- 239000011701 zinc Substances 0.000 title 1
- 229910052725 zinc Inorganic materials 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US313495P | 1995-09-01 | 1995-09-01 | |
| US003134 | 1995-09-01 | ||
| US735695P | 1995-11-20 | 1995-11-20 | |
| PCT/IB1996/000981 WO1997009976A2 (en) | 1995-09-01 | 1996-08-23 | Method of reducing neurotoxic injury with zinc chelators |
| US007356 | 1998-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6887996A true AU6887996A (en) | 1997-04-01 |
Family
ID=26671370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU68879/96A Abandoned AU6887996A (en) | 1995-09-01 | 1996-08-23 | Method of reducing neurotoxic injury with zinc chelators |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6887996A (en) |
| WO (1) | WO1997009976A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834457A (en) * | 1996-01-26 | 1998-11-10 | The Regents Of The University Of California | Method of modulating radical formation by mutant cuznsod enzymes |
| US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
| US6638711B1 (en) | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
| US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6562836B1 (en) | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| US6407090B1 (en) | 1999-06-23 | 2002-06-18 | Zinc Therapeutics Canada, Inc. | Zinc ionophores as anti-apoptotic agents |
| EP1463823B1 (en) * | 2001-12-06 | 2013-03-06 | Fibrogen, Inc. | Methods of increasing endogenous erythropoietin (epo) |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| IL151921A0 (en) * | 2002-09-25 | 2003-04-10 | Pharma Ltd D | Liphopilic diesters of chelating agent for inhibition of enzyme activity |
| EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| CA2592320C (en) | 2004-12-22 | 2015-11-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| ES2533463T3 (en) | 2006-10-12 | 2015-04-10 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| US20180071238A1 (en) * | 2015-04-10 | 2018-03-15 | Ohio University | Compositions and Methods for Traumatized Tissues Using Zinc Chelators |
| WO2016179217A1 (en) * | 2015-05-06 | 2016-11-10 | Ohio University | Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis |
| JP6958820B2 (en) | 2015-12-14 | 2021-11-02 | エックス4 ファーマシューティカルズ, インコーポレイテッド | How to treat cancer |
| CA3008272A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP7055380B2 (en) | 2015-12-22 | 2022-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Methods for treating immunodeficiency diseases |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109641838A (en) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | CXCR4 inhibitor and application thereof |
| WO2017223229A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN116554168B (en) | 2016-06-21 | 2025-09-23 | X4制药有限公司 | CXCR4 inhibitors and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3932338A1 (en) * | 1989-09-28 | 1991-04-11 | Nmi Naturwissenschaftl U Mediz | Treatment of Alzheimer's disease by chelating aluminium - using electron-rich oxine derivs., e.g. ester(s) or urethane(s) or 8-hydroxy-quinoline or -quinaldine |
| US5206264A (en) * | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| AU669493B2 (en) * | 1991-11-12 | 1996-06-13 | University Of Melbourne, The | A method for assaying and treating Alzheimer's disease |
| GB9324871D0 (en) * | 1993-12-03 | 1994-01-19 | Lilly Industries Ltd | Novel compounds |
| DE4431175A1 (en) * | 1994-09-01 | 1996-04-11 | Medico Pharma Vertriebs Gmbh | New drugs containing chelating agents |
-
1996
- 1996-08-23 AU AU68879/96A patent/AU6887996A/en not_active Abandoned
- 1996-08-23 WO PCT/IB1996/000981 patent/WO1997009976A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997009976A3 (en) | 1997-05-22 |
| WO1997009976A2 (en) | 1997-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6887996A (en) | Method of reducing neurotoxic injury with zinc chelators | |
| AU3895595A (en) | Methods of inhibiting conditions associated with neuropeptide | |
| AU7379896A (en) | Method and apparatus for improving the function of sensory cells | |
| AU4918796A (en) | Methods of treating or preventing psychiatric disorders | |
| AU1322195A (en) | Method of assay | |
| AUPN271295A0 (en) | Method of treatment | |
| AU3969295A (en) | Method of forming an absorbent article | |
| AU6400294A (en) | Tripterinin compound and method | |
| AU1683395A (en) | A method of treating glaucoma | |
| AU3730093A (en) | Methods of treating diabetes | |
| PL313740A1 (en) | Method of | |
| AU1020997A (en) | Method of treating sepsis | |
| AU6927894A (en) | 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions | |
| AU5001793A (en) | Method of decreasing cutaneous senescence | |
| AU1984195A (en) | Masking method | |
| HK1007981B (en) | Method of punching parts | |
| AU3861595A (en) | A screw and method for the manufacturing and treatment of a screw | |
| AU6973294A (en) | Method for treatment of a piece | |
| SG55119A1 (en) | Spindle unit and method of asembling the spindle unit | |
| AU7113996A (en) | Methods of treating beta-amyloid-associated conditions | |
| AU7037994A (en) | A method of galvanising | |
| AU2348492A (en) | Method of treating asthma | |
| AU1006892A (en) | Process for the electroextraction of zinc | |
| AU2381295A (en) | Method of treating allergic rhinitis | |
| AU7349496A (en) | Method for treatment of SLE |